Theravance Biopharma
South San Francisco · Founded 1996
About Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company with one approved product, VIBATIV® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. In addition, they have an economic interest in future payments that may be made by GlaxoSmithKline plc (GSK) pursuant to its agreements with Theravance, Inc. relating to certain drug programs, including the combination of umeclidinium (UMEC), vilanterol (VI) and fluticasone furoate (FF) (UMEC/VI/FF), the combination of the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) GSK961081 (‘081) and FF (‘081/FF), and MABA monotherapy.
Company Facts
- Founded: 1996
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $50K – $100K
- Total funding: $663.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2021)
- Ticker: nasdaq:THRX
- Website: theravance.com
- Phone: (650)808-4045
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/theravance-biopharma-152987 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.